The advent of concurrent chemoradiation has significantly contributed to the curability of head and neck cancer, including locoregionally advanced disease. Preserving organ function and reducing ...

P eople with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds. The results ...

Summary and Introduction Clinical Application—Disease Entities Theoretical Framework for Therapy−The 'Steel Paradigm' Conclusion References Theoretical Framework for Therapy−The 'Steel ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

in adult patients whose disease has not progressed following platinum-based chemoradiation therapy (CRT). The latest approval for Imfinzi in the European Union (EU) was based on data from the phase ...

The PACIFIC trial only enrolled patients who did not progress during chemoradiation. In practice, some patients may progress before receiving consolidation immunotherapy. Patients with locally ...

Please provide your email address to receive an email when new articles are posted on . Chemoradiation and radiation alone conferred comparable RFS and OS benefits. Grade 3/grade 4 adverse events ...

AstraZeneca’s IMFINZI TM (durvalumab) has received approval in the European Union as a monotherapy for treating adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...